Abstract:Purpose In this study, we used a series of immunohistochemical measurements of 2 cell cycle regulators, p16 and p21, to evaluate their prognostic value, separately and in combination, for the disease outcomes. Method A total of 101 patients with high-grade osteosarcoma were included in this study. Clinicopathologic data were collected, and immunohistochemistry for p16 and p21 was performed and interpreted by 3 independent pathologists. Statistical analysis was performed to assess the strength of each of these markers relative to disease outcome. Results Our results indicate that more than 90% expression (high) of p16 by immunohistochemistry on the initial biopsy has a strong predictive value for good histologic response to chemotherapy. The patients are also more likely to survive the past 5 years and less likely to develop metastasis than patients with less than 90% p16 (low) expression. The results for p21, on the other hand, show a unique pattern of relationship to the clinicopathologic outcomes of the disease. Patients with less than 1% (low) or more than 50% (high) expression of p21 by immunohistochemistry show a higher chance of metastasis, poor necrotic response to chemotherapy, and an overall decreased survival rate when compared with p21 expression between 1% and 50% (moderate). Our results also showed that the expression of p16 and combined p16 and p21 demonstrates a stronger predictive relationship to 5-year survival than tumor histologic necrosis and p21 alone. Discussion The results of this study, once proven to be reproducible by a larger number of patients, will be valuable in the initial assessment and risk stratification of the patients for treatment and possibly the clinical trials. Osteosarcoma is the most common primary malignant neoplasm of bone. Despite recent advances in the management of the disease, the overall survival of patients has failed to improve in the past 30 years due to the biological and genetic complexities of the disease and the lack of reliable prognostic and predictive markers to guide the treatments. Histologic tumor necrosis in response to chemotherapy has served as the most reliable predictor of disease outcome for years. Patients with a good histologic response (greater than 90% tumor necrosis) to chemotherapy had better disease outcomes compared with patients with a poor histologic response (less than 90% tumor necrosis). With the changes in the intensity of chemotherapeutic regimens, the prognostic value of histologic measurement of tumor necrosis has been questioned in recent studies.

Prognostic value of hemogram parameters in osteosarcoma: The French OS2006 experience

Identification of a Programmed Cell Death-related Signature for Prediction of Osteosarcoma

Three Hematological Indexes That May Serve As Prognostic Indicators in Patients with Primary, High-Grade, Appendicular Osteosarcoma

Intratumoral Heterogeneity Assessment of the Extracellular Bone Matrix and Immune Microenvironment in Osteosarcoma Using Digital Imaging to Predict Therapeutic Response

Prognostic factors in high-grade pediatric osteosarcoma among children and young adults: Greek Nationwide Registry for Childhood Hematological Malignancies and Solid Tumors (NARECHEM-ST) data along with a systematic review and meta-analysis

Prognostic Value of the Preoperative Lymphocyte-to-C-Reactive Protein Ratio and Albumin-to-Globulin Ratio in Patients with Osteosarcoma

Neutrophil-to-lymphocyte ratio and chemotherapy response score as prognostic markers in ovarian cancer patients treated with neoadjuvant chemotherapy

Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort

[Prognostic Factors for 72 Patients with Osteosarcoma of the Extremity Treated with Neoadjuvant Chemotherapy].

Prognostic relevance of early radiologic response to induction chemotherapy in pediatric rhabdomyosarcoma: A report from the International Society of Pediatric Oncology Malignant Mesenchymal Tumor 95 study

Lymphocyte-to-monocyte ratio as a prognostic and potential tumor microenvironment indicator in advanced soft tissue sarcoma treated with first-line doxorubicin therapy

Prognostic Value of Hematological Parameters in Oral Squamous Cell Carcinoma

Electrolyte prognosis scoring system can predict overall survival in patients with osteosarcoma

Identification of a biomarker to predict doxorubicin/cisplatin chemotherapy efficacy in osteosarcoma patients using primary, recurrent and metastatic specimens

Stratifying osteosarcoma patients using an epigenetic modification-related prognostic signature: implications for immunotherapy and chemotherapy selection

Prognostic role of the recepteur d'origine nantais (RON) expression in primary high-grade osteosarcoma

Prognostic value of pretreatment platelet count, fibrinogen and d-dimer levels in osteosarcoma patients: A meta-analysis

Cell Cycle Checkpoints p16 and p21—Strong Predictors of Clinicopathologic Outcomes in High-Grade Osteosarcoma

Systemic Inflammation Is Associated with Oncological Outcome in Patients with High-Grade Myxofibrosarcoma of the Extremities: A Retrospective Analysis

Clinical analysis of Chinese limb osteosarcoma patients treated by two combinations of methotrexate, cisplatin, doxorubicin and ifosfamide.

Clinical Factors Affecting Prognosis of Limb Osteosarcoma in China: a Multicenter Retrospective Analysis.